Abstract

Circadian rhythm sleep disorders (CRSDs), whether chronic or transient, affect a broad range of individuals, including many elderly, those with severe visual impairments, shift workers, and jet travelers moving rapidly across many time zones. In addition, various forms of insomnia affect another large sector of the population. A feature common among CRSDs and some forms of insomnia is sensitivity to the hormone melatonin, which is secreted by the pineal gland. Accumulating evidence suggests that melatonin may regulate the circadian clock located in the suprachiasmatic nucleus (SCN) of the hypothalamus. Although the light-dark cycle is the primary signal that entrains the circadian clock to environmental cycles, exogenous melatonin has been shown to entrain the clock in individuals with no light perception and free-running circadian rhythms. Furthermore, studies have reported beneficial effects of melatonin for treatment of certain insomnias. Together, these studies suggest that melatonin may be useful for treating some insomnias and CRSDs. In these contexts, use of melatonin as a supplement has been popular in the United States. Unfortunately, the therapeutic potential of melatonin has been difficult to realize in clinical trials, possibly owing to non-specific actions of the agent and its unfavorable pharmacokinetic properties when administered orally. In an attempt to take advantage of the therapeutic opportunities available through the brain's melatonin system, researchers have developed several melatonin agonists with improved properties in comparison to melatonin. Some of these agents are now in clinical trials for treatment of insomnia or CRSDs.

Original languageEnglish (US)
Pages (from-to)523-532
Number of pages10
JournalSleep Medicine
Volume5
Issue number6
DOIs
StatePublished - Nov 1 2004

Fingerprint

Melatonin
Circadian Rhythm
Sleep
Circadian Rhythm Sleep Disorders
Sleep Initiation and Maintenance Disorders
Circadian Clocks
Clinical Trials
Suprachiasmatic Nucleus
Pineal Gland
Vision Disorders
Photoperiod
Therapeutics
Hypothalamus
Pharmacokinetics
Research Personnel
Hormones
Light
Brain

Keywords

  • Circadian rhythm
  • Insomnia
  • Melatonin
  • Pineal gland
  • Sleep
  • Suprachiasmatic nucleus

ASJC Scopus subject areas

  • Dentistry(all)
  • Ophthalmology
  • Pulmonary and Respiratory Medicine
  • Neurology

Cite this

Melatonin, sleep, and circadian rhythms : Rationale for development of specific melatonin agonists. / Turek, Fred W.; Gillette, Martha L.

In: Sleep Medicine, Vol. 5, No. 6, 01.11.2004, p. 523-532.

Research output: Contribution to journalReview article

@article{2967dfdf5271402f99cda2875e65b2cc,
title = "Melatonin, sleep, and circadian rhythms: Rationale for development of specific melatonin agonists",
abstract = "Circadian rhythm sleep disorders (CRSDs), whether chronic or transient, affect a broad range of individuals, including many elderly, those with severe visual impairments, shift workers, and jet travelers moving rapidly across many time zones. In addition, various forms of insomnia affect another large sector of the population. A feature common among CRSDs and some forms of insomnia is sensitivity to the hormone melatonin, which is secreted by the pineal gland. Accumulating evidence suggests that melatonin may regulate the circadian clock located in the suprachiasmatic nucleus (SCN) of the hypothalamus. Although the light-dark cycle is the primary signal that entrains the circadian clock to environmental cycles, exogenous melatonin has been shown to entrain the clock in individuals with no light perception and free-running circadian rhythms. Furthermore, studies have reported beneficial effects of melatonin for treatment of certain insomnias. Together, these studies suggest that melatonin may be useful for treating some insomnias and CRSDs. In these contexts, use of melatonin as a supplement has been popular in the United States. Unfortunately, the therapeutic potential of melatonin has been difficult to realize in clinical trials, possibly owing to non-specific actions of the agent and its unfavorable pharmacokinetic properties when administered orally. In an attempt to take advantage of the therapeutic opportunities available through the brain's melatonin system, researchers have developed several melatonin agonists with improved properties in comparison to melatonin. Some of these agents are now in clinical trials for treatment of insomnia or CRSDs.",
keywords = "Circadian rhythm, Insomnia, Melatonin, Pineal gland, Sleep, Suprachiasmatic nucleus",
author = "Turek, {Fred W.} and Gillette, {Martha L}",
year = "2004",
month = "11",
day = "1",
doi = "10.1016/j.sleep.2004.07.009",
language = "English (US)",
volume = "5",
pages = "523--532",
journal = "Sleep Medicine",
issn = "1389-9457",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Melatonin, sleep, and circadian rhythms

T2 - Rationale for development of specific melatonin agonists

AU - Turek, Fred W.

AU - Gillette, Martha L

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Circadian rhythm sleep disorders (CRSDs), whether chronic or transient, affect a broad range of individuals, including many elderly, those with severe visual impairments, shift workers, and jet travelers moving rapidly across many time zones. In addition, various forms of insomnia affect another large sector of the population. A feature common among CRSDs and some forms of insomnia is sensitivity to the hormone melatonin, which is secreted by the pineal gland. Accumulating evidence suggests that melatonin may regulate the circadian clock located in the suprachiasmatic nucleus (SCN) of the hypothalamus. Although the light-dark cycle is the primary signal that entrains the circadian clock to environmental cycles, exogenous melatonin has been shown to entrain the clock in individuals with no light perception and free-running circadian rhythms. Furthermore, studies have reported beneficial effects of melatonin for treatment of certain insomnias. Together, these studies suggest that melatonin may be useful for treating some insomnias and CRSDs. In these contexts, use of melatonin as a supplement has been popular in the United States. Unfortunately, the therapeutic potential of melatonin has been difficult to realize in clinical trials, possibly owing to non-specific actions of the agent and its unfavorable pharmacokinetic properties when administered orally. In an attempt to take advantage of the therapeutic opportunities available through the brain's melatonin system, researchers have developed several melatonin agonists with improved properties in comparison to melatonin. Some of these agents are now in clinical trials for treatment of insomnia or CRSDs.

AB - Circadian rhythm sleep disorders (CRSDs), whether chronic or transient, affect a broad range of individuals, including many elderly, those with severe visual impairments, shift workers, and jet travelers moving rapidly across many time zones. In addition, various forms of insomnia affect another large sector of the population. A feature common among CRSDs and some forms of insomnia is sensitivity to the hormone melatonin, which is secreted by the pineal gland. Accumulating evidence suggests that melatonin may regulate the circadian clock located in the suprachiasmatic nucleus (SCN) of the hypothalamus. Although the light-dark cycle is the primary signal that entrains the circadian clock to environmental cycles, exogenous melatonin has been shown to entrain the clock in individuals with no light perception and free-running circadian rhythms. Furthermore, studies have reported beneficial effects of melatonin for treatment of certain insomnias. Together, these studies suggest that melatonin may be useful for treating some insomnias and CRSDs. In these contexts, use of melatonin as a supplement has been popular in the United States. Unfortunately, the therapeutic potential of melatonin has been difficult to realize in clinical trials, possibly owing to non-specific actions of the agent and its unfavorable pharmacokinetic properties when administered orally. In an attempt to take advantage of the therapeutic opportunities available through the brain's melatonin system, researchers have developed several melatonin agonists with improved properties in comparison to melatonin. Some of these agents are now in clinical trials for treatment of insomnia or CRSDs.

KW - Circadian rhythm

KW - Insomnia

KW - Melatonin

KW - Pineal gland

KW - Sleep

KW - Suprachiasmatic nucleus

UR - http://www.scopus.com/inward/record.url?scp=7044263197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044263197&partnerID=8YFLogxK

U2 - 10.1016/j.sleep.2004.07.009

DO - 10.1016/j.sleep.2004.07.009

M3 - Review article

C2 - 15511698

AN - SCOPUS:7044263197

VL - 5

SP - 523

EP - 532

JO - Sleep Medicine

JF - Sleep Medicine

SN - 1389-9457

IS - 6

ER -